A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.